News on Vascular Therapeutics Incorporated from BioPortfolio.com http://www.BioPortfolio.com Consolidated Vascular Therapeutics Incorporated news from BioPortfolio.com Wed, 10 Feb 2010 01:01:58 GMT en Capstone Therapeutics to Present at 3rd Annual European Life Science CEO Forumhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035501&HITNO=0&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035501&THISHREF=http://c.moreover.com/click/here.pl%3fz2536264763%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035501&HITNO=0&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035501&THISHREF=http://c.moreover.com/click/here.pl%3fz2536264763%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study;http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034853&HITNO=1&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034853&THISHREF=http://c.moreover.com/click/here.pl%3fz2536014104%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034853&HITNO=1&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034853&THISHREF=http://c.moreover.com/click/here.pl%3fz2536014104%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comHealthcare Sales & Marketing Network: Oraya Initiates Sham- Controlled Study of Radiation Therapy for Wet AMDhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032091&HITNO=2&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032091&THISHREF=http://c.moreover.com/click/here.pl%3fz2534500384%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032091&HITNO=2&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032091&THISHREF=http://c.moreover.com/click/here.pl%3fz2534500384%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comCataract & Refractive Surgery Today: FDA Tough on Cell Therapeutics' Drughttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030969&HITNO=3&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030969&THISHREF=http://c.moreover.com/click/here.pl%3fz2533919865%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030969&HITNO=3&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030969&THISHREF=http://c.moreover.com/click/here.pl%3fz2533919865%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTheStreet.com: FDA Tough on Cell Therapeutics' Cancer Drughttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030472&HITNO=4&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030472&THISHREF=http://c.moreover.com/click/here.pl%3fz2533646174%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030472&HITNO=4&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030472&THISHREF=http://c.moreover.com/click/here.pl%3fz2533646174%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTheStreet.com: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study;http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030796&HITNO=5&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030796&THISHREF=http://c.moreover.com/click/here.pl%3fz2533825184%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030796&HITNO=5&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030796&THISHREF=http://c.moreover.com/click/here.pl%3fz2533825184%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directorshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030113&HITNO=6&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030113&THISHREF=http://c.moreover.com/click/here.pl%3fz2533449130%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030113&HITNO=6&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030113&THISHREF=http://c.moreover.com/click/here.pl%3fz2533449130%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSmartBrief: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study;http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029889&HITNO=7&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029889&THISHREF=http://c.moreover.com/click/here.pl%3fz2533323563%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029889&HITNO=7&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029889&THISHREF=http://c.moreover.com/click/here.pl%3fz2533323563%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directorshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029441&HITNO=8&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029441&THISHREF=http://c.moreover.com/click/here.pl%3fz2533143447%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029441&HITNO=8&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029441&THISHREF=http://c.moreover.com/click/here.pl%3fz2533143447%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPhoenix Business Journal: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directorshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029365&HITNO=9&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029365&THISHREF=http://c.moreover.com/click/here.pl%3fz2533111508%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029365&HITNO=9&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029365&THISHREF=http://c.moreover.com/click/here.pl%3fz2533111508%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comAustin Business Journal: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directorshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029340&HITNO=10&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029340&THISHREF=http://c.moreover.com/click/here.pl%3fz2533094589%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029340&HITNO=10&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029340&THISHREF=http://c.moreover.com/click/here.pl%3fz2533094589%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSan Francisco Business Times: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directorshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029325&HITNO=11&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029325&THISHREF=http://c.moreover.com/click/here.pl%3fz2533090135%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029325&HITNO=11&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029325&THISHREF=http://c.moreover.com/click/here.pl%3fz2533090135%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comDenver Business Journal: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directorshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029321&HITNO=12&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029321&THISHREF=http://c.moreover.com/click/here.pl%3fz2533088559%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029321&HITNO=12&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029321&THISHREF=http://c.moreover.com/click/here.pl%3fz2533088559%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBoston Business Journal: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directorshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029314&HITNO=13&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029314&THISHREF=http://c.moreover.com/click/here.pl%3fz2533082285%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029314&HITNO=13&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029314&THISHREF=http://c.moreover.com/click/here.pl%3fz2533082285%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTriad Business Journal: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directorshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029312&HITNO=14&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029312&THISHREF=http://c.moreover.com/click/here.pl%3fz2533081904%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029312&HITNO=14&MSIZE=135&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Vascular%20Therapeutics%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029312&THISHREF=http://c.moreover.com/click/here.pl%3fz2533081904%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comOrlando Business Journal: